Termination Agreements in the Biotechnology Industry
202 Contracts & Agreements
- AbbVie Inc. (1 contract)
- ACADIA PHARMACEUTICALS INC (2)
- ACHIEVE LIFE SCIENCES, INC. (2)
- Acorda Therapeutics (1)
- Adaptimmune Therapeutics PLC (1)
- ADURO BIOTECH, INC. (1)
- Advaxis, Inc. (1)
- AGENUS INC (1)
- Akebia Therapeutics, Inc. (3)
- Allakos Inc. (2)
- Alliqua BioMedical, Inc. (6)
- Allovir, Inc. (1)
- ALNYLAM PHARMACEUTICALS, INC. (2)
- Altimmune, Inc. (1)
- AMICUS THERAPEUTICS, INC. (5)
- AmpliPhi Biosciences Corp (1)
- ANAVEX LIFE SCIENCES CORP. (1)
- Anchiano Therapeutics Ltd. (1)
- Anixa Biosciences Inc (1)
- AQUINOX PHARMACEUTICALS, INC (1)
- Arcturus Therapeutics Holdings Inc. (1)
- ARDELYX, INC. (2)
- ARENA PHARMACEUTICALS INC (6)
- Atara Biotherapeutics, Inc. (1)
- Athenex, Inc. (1)
- ATHERSYS, INC (1)
- ATOSSA GENETICS INC (1)
- BeiGene, Ltd. (4)
- BioCardia, Inc. (1)
- BIOCEPT INC (1)
- BIOCRYST PHARMACEUTICALS INC (2)
- Biogen Inc. (1)
- BIOMARIN PHARMACEUTICAL INC (3)
- BIOTIME INC (1)
- Blueprint Medicines Corp (2)
- BRAINSTORM CELL THERAPEUTICS INC. (1)
- Caribou Biosciences, Inc. (1)
- Castle Creek Biosciences, Inc. (1)
- CATALYST BIOSCIENCES, INC. (1)
- CATALYST PHARMACEUTICALS, INC. (1)
- CEREBAIN BIOTECH CORP. (3)
- Checkpoint Therapeutics, Inc. (2)
- Conatus Pharmaceuticals Inc. (6)
- CRISPR Therapeutics AG (1)
- CTI BIOPHARMA CORP (5)
- Cue Biopharma, Inc. (1)
- CURIS INC (1)
- CytoDyn Inc. (1)
- CYTRX CORP (1)
- Editas Medicine, Inc. (1)
- Emerald Bioscience, Inc. (1)
- Esperion Therapeutics, Inc. (1)
- Exelixis (2)
- EXICURE, INC. (1)
- Fibrocell Science, Inc. (1)
- G1 Therapeutics, Inc. (1)
- HALOZYME THERAPEUTICS INC (1)
- HEAT BIOLOGICS, INC. (1)
- HEMISPHERX BIOPHARMA INC (3)
- HISTOGENICS CORP (1)
- Homology Medicines, Inc. (1)
- HOOKIPA Pharma Inc. (1)
- HUMANIGEN, INC (4)
- iBio, Inc. (1)
- IMMUNE PHARMACEUTICALS INC (2)
- IMMUNOGEN INC (1)
- IMMUNOMEDICS INC (4)
- INFINITY PHARMACEUTICALS, INC. (2)
- Inhibrx, Inc. (1)
- Innovation Pharmaceuticals Inc. (1)
- INOVIO PHARMACEUTICALS, INC. (1)
- Inspyr Therapeutics, Inc. (1)
- Isoray, Inc. (1)
- KBL MERGER CORP. IV (1)
- LA JOLLA PHARMACEUTICAL CO (1)
- LEXICON PHARMACEUTICALS, INC. (1)
- Ligand Pharmaceuticals Incorporated (1)
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. (1)
- MATEON THERAPEUTICS INC (1)
- MEI Pharma, Inc. (2)
- MeiraGTx Holdings plc (1)
- Millendo Therapeutics, Inc. (1)
- Molecular Templates, Inc. (1)
- NAVIDEA BIOPHARMACEUTICALS, INC. (2)
- NEUROBIOLOGICAL TECHNOLOGIES INC (2)
- NORTHWEST BIOTHERAPEUTICS INC (1)
- NOVAVAX INC (1)
- NUTRA PHARMA CORP (1)
- OncBioMune Pharmaceuticals, Inc (2)
- OncoCyte Corp (2)
- Opko Health, Inc. (2)
- Orgenesis Inc. (1)
- Outlook Therapeutics, Inc. (1)
- Ovid Therapeutics Inc. (1)
- PALATIN TECHNOLOGIES INC (3)
- Pfenex Inc. (1)
- PharmaCyte Biotech, Inc. (2)
- POLARITYTE, INC. (1)
- PREDICTIVE TECHNOLOGY GROUP, INC. (1)
- Propanc Biopharma, Inc. (1)
- PROTEOSTASIS THERAPEUTICS, INC. (1)
- Prothena Corp plc (1)
- PUMA BIOTECHNOLOGY, INC. (1)
- Qrons Inc. (0)
- Regeneron Pharmaceuticals (2)
- RenovaCare, Inc. (1)
- REXAHN PHARMACEUTICALS, INC. (1)
- Rezolute, Inc. (2)
- RIGEL PHARMACEUTICALS INC (1)
- RITTER PHARMACEUTICALS INC (2)
- ROCKET PHARMACEUTICALS, INC. (1)
- SANGAMO THERAPEUTICS, INC (1)
- SEATTLE GENETICS INC (1)
- SELLAS Life Sciences Group, Inc. (1)
- Seres Therapeutics, Inc. (0)
- Shattuck Labs, Inc. (1)
- Sierra Oncology, Inc. (1)
- Sorrento Therapeutics, Inc. (1)
- Spero Therapeutics, Inc. (2)
- SpringWorks Therapeutics, Inc. (1)
- SUNESIS PHARMACEUTICALS INC (2)
- Surface Oncology, Inc. (2)
- Syndax Pharmaceuticals Inc (2)
- Synthetic Biologics, Inc. (1)
- TENAX THERAPEUTICS, INC. (1)
- Trovagene, Inc. (1)
- U.S. Stem Cell, Inc. (1)
- uniQure N.V. (1)
- Vaxart, Inc. (1)
- Vericel Corp (1)
- VICAL INC (2)
- Vir Biotechnology, Inc. (1)
- Voyager Therapeutics, Inc. (1)
- Xenon Pharmaceuticals Inc. (2)
- YIELD10 BIOSCIENCE, INC. (1)
- Termination and Settlement Agreement, dated July 10, 2024, by and between the Company and Vifor (International) Ltd (Akebia Therapeutics, Inc., Filed With SEC on August 8, 2024)
- Termination Agreement, dated July 22, 2024, by and between uniQure biopharma B.V. and Pierre Caloz (uniQure N.V., Filed With SEC on August 1, 2024)
- Termination Agreement, dated July 1, 2024, by and between AlloVir, Inc. and BP Bay Colony LLC (Allovir, Inc., Filed With SEC on July 2, 2024)
- Mutual Termination and Release Agreement, dated as of June 3, 2024, by and among LadRx Corporation, NantCell, Inc., ImmunityBio, Inc. and XOMA (US) LLC (CYTRX CORP, Filed With SEC on June 6, 2024)
- Termination of Consultancy Service Agreement between Hookipa Biotech GmbH and Malte Peters, effective March 31, 2024 (HOOKIPA Pharma Inc., Filed With SEC on May 9, 2024)
- Consent and Termination Agreement, dated February 22, 2024, by and between the Registrant and Royalty Pharma Investments 2019 ICAV (Blueprint Medicines Corp, Filed With SEC on May 2, 2024)
- Termination Agreement dated as of March 16, 2024 between the Company and Pan-RAS Holdings, Inc (RITTER PHARMACEUTICALS INC, Filed With SEC on March 28, 2024)
- Mutual Termination Agreement (Collaboration) by and between Checkpoint Therapeutics, Inc. and TG Therapeutics, Inc. dated September 30, 2023 (Checkpoint Therapeutics, Inc., Filed With SEC on March 22, 2024)
- Mutual Termination Agreement (Sublicense) by and between Checkpoint Therapeutics, Inc. and TG Therapeutics, Inc. dated September 30, 2023 (Checkpoint Therapeutics, Inc., Filed With SEC on March 22, 2024)
- Termination Agreement, dated December 20, 2023, by and among Janssen Pharmaceuticals, Inc., MeiraGTx UK II Limited and MeiraGTx Holdings plc (MeiraGTx Holdings plc, Filed With SEC on March 15, 2024)
- Termination of License Agreement, dated as of March 1, 2024, by and between Fresh Tracks Therapeutics, Inc. and Carna Biosciences, Inc (VICAL INC, Filed With SEC on March 7, 2024)
- Termination Agreement, dated February (Inhibrx, Inc., Filed With SEC on February 28, 2024)
- Termination and Settlement Agreement, dated as of February 16, 2024, between the Company and Gavi Alliance (NOVAVAX INC, Filed With SEC on February 28, 2024)
- First Amendment to the Settlement and Termination Agreement, dated as of January 10, 2024, by and between the Registrant, BeiGene Switzerland GmbH, Bristol-Myers Squibb Company,... (BeiGene, Ltd., Filed With SEC on February 26, 2024)
- JVA Termination Agreement, by and among Biogen Therapeutics Inc., Samsung BioLogics Co., Ltd. and Samsung Bioepis Co., Ltd, dated April 20, 2020 (Biogen Inc., Filed With SEC on February 14, 2024)
- Termination Agreement, dated November 10, 2023, between Q32 Bio Inc. and Horizon Therapeutics DAC (Homology Medicines, Inc., Filed With SEC on December 18, 2023)
- Mutual Termination and Release Agreement, dated September 17, 2023, by and between BeiGene Switzerland GmbH and Novartis Pharma AG (BeiGene, Ltd., Filed With SEC on November 9, 2023)
- Settlement and Termination Agreement, dated as of August 1, 2023, by and between the Registrant, BeiGene Switzerland GmbH, Bristol-Myers Squibb Company, Celgene Corporation,... (BeiGene, Ltd., Filed With SEC on November 9, 2023)
- Notice of Termination and Letter Agreement, dated September 18, 2023, by and between the Company and Joyce Reyes (Conatus Pharmaceuticals Inc., Filed With SEC on November 9, 2023)
- Notice of Termination and Letter Agreement, dated September 18, 2023, by and between the Company and Alfred P. Spada (Conatus Pharmaceuticals Inc., Filed With SEC on November 9, 2023)
- Notice of Termination and Letter Agreement, dated September 18, 2023 by and between the Company and Steven J. Mento (Conatus Pharmaceuticals Inc., Filed With SEC on November 9, 2023)
- Termination letter between H. Lee Moffitt Cancer Center and Research Institute, Inc. and the Company dated October 4, 2023 and effective as of September 30, 2023 (LIXTE BIOTECHNOLOGY HOLDINGS, INC., Filed With SEC on November 9, 2023)
- Termination Letter (Oxford License) September 22, 2023 (KBL MERGER CORP. IV, Filed With SEC on September 28, 2023)
- Mutual Termination and Release Agreement, dated September 21, 2023, between Sorrento Therapeutics, Inc. and Oramed Pharmaceuticals, Inc (Sorrento Therapeutics, Inc., Filed With SEC on September 26, 2023)
- Mutual Termination and Release Agreement, dated July 10, 2023, by and between BeiGene Switzerland GmbH and Novartis Pharma AG (BeiGene, Ltd., Filed With SEC on August 2, 2023)
- Termination Letter from MEI Pharma, Inc. to Infinity Pharmaceuticals, Inc., dated July 23, 2023 (MEI Pharma, Inc., Filed With SEC on July 24, 2023)
- Termination Agreement, by and between MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. (formerly known as Kyowa Hakko Kirin Co., Ltd.) dated as of July 14, 2023 (MEI Pharma, Inc., Filed With SEC on July 19, 2023)
- Mutual Termination Agreement, effective as of April 30, 2023, by and between F. Hoffman La Roche Ltd, Hoffman-La Roche Inc. and the Registrant (Blueprint Medicines Corp, Filed With SEC on May 4, 2023)
- Termination and Transfer Agreement made and effective as of April 6, 2023 by and between Adaptimmune Limited and GlaxoSmithKline Intellectual Property Development Ltd (Adaptimmune Therapeutics PLC, Filed With SEC on April 11, 2023)
- Termination and Settlement Agreement, dated December 22, 2022, by and between Keryx Biopharmaceuticals, Inc. and BioVectra Inc (Akebia Therapeutics, Inc., Filed With SEC on March 10, 2023)
- Mutual Termination Agreement dated December 22, 2022, by and between Amicus Therapeutics, Inc. and the Trustees of the University of Pennsylvania (AMICUS THERAPEUTICS, INC., Filed With SEC on March 1, 2023)
- Termination Agreement, dated February 7, 2023, by and between Oncocyte Corporation and Life Technologies Corporation (OncoCyte Corp, Filed With SEC on February 13, 2023)
- Mutual Termination Agreement, dated December 12, 2022, by and between Exicure, Inc. and Ipsen Biopharm Limited (EXICURE, INC., Filed With SEC on December 14, 2022)
- Termination of License Agreement, dated September 9, 2022, between Cue Biopharma, Inc. and MIL 21E, LLC (Cue Biopharma, Inc., Filed With SEC on November 14, 2022)
- Termination Agreement and Release dated September 19, 2022 by and between iBio, Inc. and RubrYc Therapeutics, Inc (iBio, Inc., Filed With SEC on November 14, 2022)
- Termination, Amendment and Program Transfer Agreement dated August 2, 2022, by and between Atara Biotherapeutics, Inc., and Bayer AG (Atara Biotherapeutics, Inc., Filed With SEC on November 8, 2022)
- August 10, 2022 Termination agreement with Shenzhen Smoore Technology Limited (HEMISPHERX BIOPHARMA INC, Filed With SEC on August 15, 2022)
- Termination Agreement between the Company and WuXi Biologics (Hong Kong) Limited dated May 16, 2022 (Vir Biotechnology, Inc., Filed With SEC on August 9, 2022)
- Amendment No 1. to the Asset Return and Termination Agreement, by and between Baxalta Incorporated and CTI BioPharma Corp., dated as of May 31, 2022 (CTI BIOPHARMA CORP, Filed With SEC on August 8, 2022)
- Termination and Settlement Agreement, dated (Akebia Therapeutics, Inc., Filed With SEC on August 4, 2022)
